10x Genomics scored a strong price increase on investors' optimism surrounding the recent announcement that its Xenium In Situ platform was used in a study published in the Journal of Dental Research, offering novel insights into cellular mechanisms regulating the formation of the secondary palate. Additionally, the company is slated to report its second-quarter 2024 financial results on Aug 8, after the closing bell. The Zacks Consensus Estimate for the second quarter revenue and earnings indicate a 3.1% a ...